RCUS
RCUS
NYSE · Biotechnology

Arcus Biosciences Inc

$25.68
+0.18 (+0.71%)
As of May 9, 1:27 AM ET ·
Financial Highlights (FY 2026)
Revenue
285.65M
Net Income
-408,239,937
Gross Margin
Profit Margin
-142.9%
Rev Growth
+30.2%
D/E Ratio
0.16
Revenue & Net Income
Margin Trends
FY 2026 FY 2025 FY 2024 FY 2023
Gross Margin 44.4% 44.4%
Operating Margin -156.3% -140.7% -6.5% -6.4%
Profit Margin -142.9% -135.8% -8.0% -7.2%
Income Statement
FY 2026 FY 2025 FY 2024 FY 2023
Revenue 285.65M 219.46M 841.86M 875.48M
Gross Profit 374.19M 389.13M
Operating Income -446,411,816 -308,674,427 -54,514,708 -55,744,444
Net Income -408,239,937 -282,280,226 -67,570,170 -63,346,573
Gross Margin 44.4% 44.4%
Operating Margin -156.3% -140.7% -6.5% -6.4%
Profit Margin -142.9% -135.8% -8.0% -7.2%
Rev Growth +30.2% +30.2% +8.2% -1.2%
Balance Sheet
FY 2026 FY 2025 FY 2024 FY 2023
Total Debt 216.29M 216.29M 401.69M 484.63M
Total Equity 1.38B 1.38B 1.67B 1.64B
D/E Ratio 0.16 0.16 0.24 0.30
Cash Flow
FY 2026 FY 2025 FY 2024 FY 2023
EBITDA -434,832,420 -317,371,541 -58,220,570 -69,808,840
Free Cash Flow -41,442,789 -42,253,468